This study is a multicenter phase Ⅲ trial. The objective is to compare the efficacy and toxicity of cisplatin plus raltitrexed or 5-fluorouracil in concurrence with IMRT for patients with locoregionally advanced head and neck squamous cell cancer.
The objective is to compare the efficacy and toxicity of cisplatin plus raltitrexed or 5-fluorouracil in concurrence with IMRT for patients with locoregionally advanced head and neck squamous cell cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Patients will receive IMRT and concurrent raltitrexed and cisplatin
Patients will receive IMRT and concurrent 5-Fu and cisplatin
All patients will receive concurrent cisplatin.
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
RECRUITINGProgression-free survival (PFS)
Time frame: 36 months
Overall Survival (OS)
Time frame: 36 months
Locoregional and distant control rate
Time frame: 36 months
Percentage of participants experiencing grade 3-5 adverse events(AEs)
Time frame: 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
All patients will receive IMRT